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ABSTRACT 
 
Abdallah, Hagar, M. M.S., Department of Chemistry, Wright State University, 2010. 
Small Molecule Caspase Inhibitors Using Isatin and Oxindole Scaffolds and a 
Combinatorial Approach. 
 
 
Quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl ketone (Q-VD-OPh) is a 
next generation broad spectrum caspase inhibitor, the effectiveness and reduced toxicity 
of which can be partially attributable to the carboxyterminal O-phenoxy group as well as 
the amino terminal quinolyl groups. We seek to incorporate some of these unique 
recognition elements onto small molecule derived protease inhibitors with drug like 
properties. Specifically, heterocyclic scaffolds such as isatins and oxindoles. Thus, isatins 
bearing electron withdrawing groups on C-5 and 2,6-difluorobenzyl moieties have been 
prepared by analogy to the well studied N-substituted 5-pyrrololidinylsulfonyl isatins. 
Moreover, 3-benzylidene oxindole derivatives bearing these structural motifs have also 
been prepared and their effectiveness as apoptosis inhibitors was examined employing 
human Jurkat T cells.  
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INTRODUCTION 
 
Apoptosis, or programmed cell death, is a biological process in which individual 
old or damaged eukaryotic cells are signaled to commit suicide.  It is a critical process in 
the maintenance of homeostasis between cell growth and cell death.  As with most 
biological processes, excessive activity or inactivity can have many outcomes.  
Uncontrolled apoptosis has been associated with diseases such as cancer, Huntington‟s 
disease, and myocardial infarctions.  Unlike necrosis, apoptosis is a clean, self contained 
process.
1
 During necrotic cell death, the cell swells and eventually bursts.  Cellular debris 
is left behind and can trigger an immune response; mainly inflammation.
1
 During 
apoptosis, the cell will shrink upon itself and the DNA will fragment.  The cell membrane 
will also collapse and the cell will split into small apoptotic bodies.  These apoptotic 
bodies can then be phagocytosed by macrophages, a type of white blood cell.   
During apoptosis, cell death can occur through two different signaling pathways: 
intrinsically and extrinsically.  In the intrinsic pathway, the signal that triggers cell death 
comes from within the cell itself.
2
 This can result from DNA damage, heat shock, or a 
defective cell cycle. This pathway involves the release of pro-apoptotic proteins from the 
mitochondria.  In the extrinsic pathway, the death signal comes from outside of the cell 
through pro-apoptotic receptors on the cell membrane.  Pro-apoptotic ligands bind to the 
pro-apoptotic receptors on the cell membrane.  Once cell death is signaled, whether it is 
by an intrinsic or extrinsic signaling mechanism, a series of cysteinyl aspartic proteases 
 
2 
 
(caspases) are activated to carry out apoptosis.  The purpose of this research is twofold: 
1) to synthesize and characterize new, potent caspase inhibitors for biological screening 
and 2) to build a combinatorial library using isatin and oxindole scaffolds that may also 
have some biological activity.  This work is based on previous research as well as new 
insight for possible inhibitor potency and combinatorial library synthesis. 
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BACKGROUND 
Recent studies have shown that caspases are critical enzymes in the activation and 
execution of apoptosis.  They have also been shown to play important roles in 
inflammation and cytokine maturation. Within the caspase family are caspases 2, 8, 9 and 
10, which are the initiator caspases.  These initiator caspases are signaled by intrinsic or 
extrinsic pathways of the apoptotic process and activate the effector caspases, which are 
caspases 3, 6 and 7.  Caspases 1, 4 and 5 are reported to be involved in inflammation, not 
in apoptosis.  Caspase-3 is the dominant effector caspase involved in the cleavage of 
DNA repair enzymes, nuclear lamins and regulatory proteins during apoptosis.
1, 2
  
Caspases recognize a specific tetrapeptide chain within the amino acid sequence 
of the substrate (target), and that is the P4-P3-P2-P1 sequence.
3
 These are the peptides that 
the caspase will cleave to begin apoptosis.  It is very critical that the P1 residue in the 
amino acid sequence be aspartic acid.  For example, poly (ADP-ribose)polymerase or  
PARP, is a DNA repair enzyme that contains the cleavage sequence D-E-V-D  (P4-P3-P2-
P1) where D is aspartic acid, E is glutamic acid and V is valine as shown in Figure 1. 
 
 
 
Figure 1 
Caspases are a class of protease enzymes which catalyze the hydrolysis of amide 
bonds through nucleophilic attack by the activated cysteine thiol from the enzyme onto 
the amide carbonyl bond of the amino acid.  The site of cleavage by the caspase (
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Enzyme) is between the P1 residue and the adjacent (carboxyterminal side) P1‟ residue.  
The mechanism of this nucleophilic attack is shown in Scheme 1. 
Scheme 1 
 
 
 
 
The corresponding binding sites for the P4-P3-P2-P1 residues on the substrates are 
called the S4-S3-S2-S1 subsites on the caspase respectively.
4
 The cysteine residue of the 
caspase will attack the protein as a nucleophile at the amide carbonyl leading to the 
formation of a tetrahedral intermediate which upon reformation of the double bond will 
result in the subsequent cleavage of the peptide bond. 
Peptide derived inhibitors which utilize this mechanism of action were the first 
type of caspase inhibitors studied in this field.  In general, such inhibitors contain an 
electrophilic functionality termed the “warhead” which can in some cases react with the 
active-site cysteine residue. The warhead functionality is also very important for the 
ability to bind to the caspase.  There are two types of warheads, the reversible and the 
irreversible functionalities.  Reversible warheads are functional groups that bind to the 
caspase temporarily as through a tetrahedral intermediate and can then be released; these 
groups include ketones, aldehydes and nitriles.   Irreversible warhead functional groups 
are usually good leaving groups, so when the caspase attacks as a nucleophile, the 
enzyme becomes covalently attached to the inhibitor and releasing (ideally) a non-toxic 
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and virtually harmless leaving group.  Examples of irreversible warhead functional 
groups are acyloxymethylketones and halomethylketones.   
 Several peptide inhibitors have been synthesized and studied, including two 
potent inhibitors acetyl-aspartyl-glutamyl-N-(2-carboxy-1-formylethyl)-valinamide (Ac-
DEVD-CHO)
5
 and quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl 
ketone (Q-VD-OPh)
5
.  Ac-DEVD-CHO (2) is an effective and widely studied caspase 
inhibitor in vitro.    
 
 
 
 
2 
Unfortunately, compound 2 has a number of undesirable characteristics, including 
three CO2H groups which decrease its ability to penetrate cells for in vivo studies.  Also, 
the warhead functionality in this case is an aldehyde, which makes the inhibitor 
reversible.  Aldehydes are also susceptible to attack by several classes of cellular 
nucleophiles in the body thereby limiting specificity; additionally, this group can also 
undergo oxidation.
4,5
 Q-VD-OPh (3), a closely related peptide inhibitor was examined 
and found to have inhibition concentrations as low as 5µM.
5 
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3 
Q-VD-OPh was found to be non-toxic to cells, even at very high concentrations 
and contained an irreversible warhead functionality, the difluorophenoxy group.  It was 
determined that the specificity and effectiveness of Q-VD-OPh was partially due to the 
difluorophenoxy warhead group.
5
   
The broad spectrum caspase inhibitor Q-VD-OPh has been used to treat hypoxic-
ischemic (HI) injury in the developing brain of P7 rats by Renolleau et al.
6
  HI injury is 
directly linked to the development of apoptosis in a post-stroke brain.  In this study, Q-
VD-OPh was administered to rats of both genders after the onset of HI injury and the 
effects of the drug were monitored for a period of three weeks after administration.  It 
was found that Q-VD-OPh greatly inhibited caspase-3 cleavage into its active p17 form, 
which is the conformation of the enzyme required to initiate apoptosis.  Also, these 
authors found that the rats that were treated with Q-VD-OPh had significant neurological 
recovery in the first 48 h of recovery time.  Another interesting find was that there was a 
significant difference in recovery and neuroprotection between the male and female rats.  
The females were more strongly protected neurologically than the males.  Moreover, the 
females showed a decrease in the release of cytochrome c, a protein responsible for 
apoptosis.  This study indicates that Q-VD-OPh was an effective caspase inhibitor in the 
central nervous system.        
O
O
F
F
N
H
O
H
N
O
O
N
OH
 
7 
 
Q-VD-OPh has also been found to be an effective caspase inhibitor in Parkinson‟s 
disease (PD) and Huntington‟s disease (HD) models.  A study conducted by Yang et al.
7
 
used a number of different mitochondrial toxins to model these two diseases.  1-Methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was used to model PD and 3-nitropropionic 
acid (3NP) and malonic acid (MA) were used to model HD.
7
 These neurotoxins create 
lesions in the brain that model the affects of these neurodegenerative diseases.  Using 
mice as the test subjects, Q-VD-OPh was injected 12 h before the injection of the 
neurotoxins and continued for several days.  After 7 days, the mice were sacrificed and 
their brains were collected for examination.  In Figure 2, a difference in the levels of 
neurotoxins can be clearly seen in the mesencephalons of the control mice and the mice 
treated with Q-VD-OPh.       
 
Figure 2 
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The arrows in Figure 2 show the lesions formed from the neurotoxins in the 
mesencephalon.
7
  The control mice show large lesions while the mice injected with Q-
VD-OPh and the neurotoxins show smaller lesions.  It is clear from Figure 2 that Q-VD-
OPh had a significant effect in protecting the mice against neurodegeneration. 
While both Ac-DEVD-CHO and Q-VD-OPh are effective caspase inhibitors, they 
are not “drug-like” due to their peptide features.  There are several disadvantages to 
peptide based inhibitors, including the fact that they are inherently peptides and can be 
metabolized in vivo; causing the drug to lack bioavailability.  Also, they are relatively 
large and polar molecules, making it difficult to cross the Blood Brain Barrier (BBB).  It 
is crucial for these inhibitors to cross the BBB for application to neurological disorders 
such as Parkinson‟s disease, Alzheimer‟s and Huntington‟s disease.  Peptide inhibitors 
also have rapid physiological clearing times, by which they pass through the kidney and 
do not come back out again.    
Consideration of the limitations inherent in the use of peptide-based caspase 
inhibitors for controlling cell death led to a search for potent small molecule inhibitors. 
High throughput screening of the SmithKline Beecham (SKB) compound collection for 
inhibitors of caspase-3 resulted in identification of 5-nitroisatins 4 and 5 which possessed 
IC50s of 0.25 and 1 µM, respectively.  The closely related unalkylated analogue 6 was 
only slightly less active (IC50 = 3 µM).
8
 A correlation between the electron-withdrawing 
ability of the C-5 carbon and the potency of inhibition suggested that the electrophilicity 
of the C-3 carbonyl was critical for activity and that the mechanism of action involved 
addition of the catalytic cysteine residue of the enzyme to this functionality.  
 
9 
 
 
 
 
 
 
 
 
 
 
Isatin (7) is an attractive scaffold for many reasons; it is small and does not have 
any peptide-like features.  Also, isatin-based drugs can potentially cross the BBB due to 
their relatively small size. Additionally, this scaffold allows for facile functionalization of 
both the aromatic ring as well as the heterocyclic nitrogen.  Alkylation of the heterocyclic 
nitrogen can be performed under normal basic conditions whereas the introduction of 
electron withdrawing groups (EWGs) at the C-5 position on the aromatic ring can easily 
be accomplished by electrophilic aromatic substitution processes.  Thus, this compound 
became the lead in a drug discovery program designed to develop potent, non-peptide 
caspase inhibitors.  With two points of variability on the SKB lead being at the C-3 and 
the C-5 positions, a combinatorial library was produced using several EWGs at the C-5 
position as well as various alkylating agents for the amide nitrogen.   
GlaxoSmithKline (GSK) employed the lead compound found by SKB as a 
potential scaffold for a Structure -Activity Relationship (SAR) study designed to find the 
optimal combination of functional groups on the scaffold.
9
 The first region inspected was 
the C-5 region.  The main goal was to find an EWG that was irreducible in vivo and could 
withdraw electron density away from the C-3 region to allow for nucleophillic attack by 
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the activated cysteine residue of the caspase.  While the lead compound contained a -NO2 
group as the EWG, unfortunately this group can be reduced in the body to amines and 
poses toxicity issues.  Several different EWG on the C-5 position were synthesized and 
tested for inhibition capabilities as shown in Figure 3.  The inhibition concentrations 
after 50% inhibition (IC50) values are reported under each compound.  It is important to 
note that the lower the IC50 the more potent the compound.  The N-methyl isatin 
compound had a fairly high IC50 value, while just adding a -NO2 group greatly increases 
its potency to 1µM.
9
 Positioning a cyano group at the C-5 position led to an increase in 
potency to 0.6 µM, whereas an iodo substituent was found to decrease activity, 
presumably due to size. Finally, carboxylic acid derivatives were examined wherein the 
carboxylate ester was less effective for inhibition while the carboxylate salt practically 
ineffective.  
 
 
 
 
 
 
 
Figure 3 
Further development led to the identification of the 5-N,N-dialkylisatin 
sulfonamide 8 as a potential inhibitor scaffold.  This functionality was seemingly ideal 
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since it incorporated an irreducible, strongly EWG at the C-5 position, while allowing for 
further elaboration of the groups on the sulfonamide nitrogen so as to extend to the 
crucial S2-S4 subsites responsible for determining specificity between the different 
caspases. 
 
 
8 
A group from Washington University in St. Louis (WashU) decided to build upon 
the GSK-SAR study.
10
 They found that not only did the sulfonamide allow for various 
dialkylated species, it also allowed for the incorporation of rings of different sizes.  
Variation of the ring size on the sulfonamide was found to make a dramatic impact on the 
IC50 values with the results shown in Figure 4. 
 
 
 
 
 
 
 
 Figure 4 
In general, based on the IC50‟s of the compounds in Figure 4, the larger the ring, 
the less potent the compound becomes.  Even though the azetidine ring had a lower IC50, 
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the pyrrolidine ring was chosen as the optimal ring size for further studies due to the ease 
of adding groups to the pyrrolidine ring via chiral proline derivatives.
10
 Ultimately, the 
WashU group found that addition of a 2-phenoxymethyl group in the (S)-configuration on 
the pyrrolidine ring resulted in an increase in potency of the resultant isatin sulfonamide 
to an IC50 of 240 nM.  As stated earlier, elaboration of the substituents at the C-2 position 
of the pyrrolidine derivatives allows for extension into the S2-S4 pockets enabling 
modulation of both potency and specificity. For example, addition of a pyridinoxymethyl 
group in place of the phenoxymethyl group was also examined and the resultant 
compound was found more potent than the phenoxymethyl analogues.
10
   
The next region of interest on the C-5 isatin sulfonamides was the isatin amide 
nitrogen.  Alkylation of the amide nitrogen was found to greatly increase the potency of 
the inhibitor, as shown in Figure 5.  Adding progressively larger groups on the amide 
nitrogen, such as a methyl group and a benzyl group, the inhibitor becomes progressively 
more potent.  Groups such as benzyl and substituted benzyl groups have been studied and 
tested for caspase inhibition with much success.
10
 The incorporation of a pyridine ring on 
the amide nitrogen was also proposed due to the success of the pyridoxymethyl ring on 
the C-5 extended sulfonamide.   
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Figure 5 
A comparison between the phenoxymethyl analogue and the pyridoxymethyl 
analogue showed increased inhibition properties for the pyridine derivatives as shown in 
Table 1.   
 
 
 
Table 1: Comparison of Phenoxymethyl and Pyridinoxymethyl Rings 
 
R 
IC50 (nM)  
Phenoxymethyl Ring 
(A) 
IC50 (nM) 
Pyridinoxymethyl Ring 
(B)  
OCH3  
 
14.5 
 
5.2 
SCH3  
 
12.4 
 
3.9 
F  
 
12.1 
 
4.4 
N O
O
H2C
S
O
O
N
O
IC50 2.5 nM
N O
O
H
S
O
O
N
O
N O
O
H
S
IC50 2800 nM
O
O
N
IC50 120 nM
N O
O
CH3
S
O
O
N
O
IC50 30 nM
N O
O
H
S
O
O
N
O
IC50 240 nM
N O
O
R
S
O
O
N
O
A
N O
O
R
S
O
O
N
O
N
B
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A summary of the SAR study is presented in Figure 6.  By having two main 
functional sites, the WashU investigators were able to vary three different regions on 
their inhibitors.   
 
 
 
 
 
Figure 6 
The WashU group also built upon their own isatin sulfonamide scaffold by adding 
a third point of variation on the C-3 carbon of isatin.
10
 By having an EWG at the C-5 
position and a group on the amide nitrogen, this group was able to functionalize the C-3 
carbonyl to form an isatin Michael acceptor (IMA) featuring a dicyano vinyl group as the 
acceptor.  By adding the dicyano group to the C-3 position, the specificity of the inhibitor 
towards the effector caspases changed. For example, Figure 7 shows the IC50‟s of two 
inhibitors, one with a carbonyl at C-3 and the other with the IMA at C-3. 
 
 
 
 
 
Figure 7 
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Based on the IC50‟s of the two inhibitors in Figure 7, the IMA favored caspase-6 
while the isatin analogue was more potent against caspase-3.
10
 Such differentiation is 
important due to the fact that different diseases carry out apoptosis via different caspases.  
Alzheimer‟s disease executes apoptosis via caspase-3 while Huntington‟s disease 
operates mainly via caspase-6.  However, as designed, there is a limitation to the IMA as 
regards to further development in that the C-3 position cannot be further functionalized 
beyond the two requisite cyano groups.   
Previous to this, Dr. Edward Brush of Bridgewater State College introduced a 
Michael acceptor onto an oxindole scaffold at the C-3 position, creating 3-
methyleneoxindole (9).
11
  The methylene oxindole scaffold 10 is very similar to isatin 
(7), with the exception of a CH2 group present at the C-3 position rather than a carbonyl. 
 
 
 
Since the activated cysteine residue of the caspase can be considered a “soft” 
nucleophile, the corresponding “soft” -position of methylene oxindole may allow such 
substrates to act as effective Michael acceptors for the inhibition of caspases as well as 
other cysteine proteases.  
More recently, a group in Australia discovered a new mechanism of action 
between their peptide inhibitors and caspase-1.
12 
As mentioned earlier, the activated 
cysteine thiol acts as a nucleophile, which attacks at the carbon of the warhead bearing a 
leaving group and covalently bonds to the inhibitor at that site.  Löser et al. showed that it 
N O
H
3
2
1
4
5
6
7
10
N O
H


9
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was not necessary to have an electrophilic warhead on the peptide inhibitor to have 
inhibitory capabilities.  They instead used a variety of secondary and tertiary amines as 
the warhead, as shown by the secondary amine bearing a phenol ring on the C-terminal 
side of the modified P1 aspartic acid group in structure 11.  By doing this, they were able 
to show that covalent interactions between key subsites on caspase-1 and the inhibitor 
can produce potent, reversible inhibitors.
12
 This work is also important due to the fact that 
secondary and tertiary amines are stable in vivo, meaning that the inhibitor has high 
bioavailability and stability.    
 
 
 
11 
 When tested against caspase-1, it was found that the amine nitrogen was 
positioned in the substrate binding groove between the Cys 285 and the His 237 residues, 
and the 2-hydroxybenzylamine was positioned in the S1‟ subsite.
12
  Shown in Figure 8 is 
a model conformation of 11 in the active site of caspase-1.  This figure demonstrates that 
there is appreciable hydrogen bonding between the 2-hydroxybenzylamine and the Asp 
288 residue in the S1‟ subsite, and also between the amine nitrogen and the His 237 
residue as shown by the dashed lines. 
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Figure 8 
This research performed by Löser et al. is significant because it proposes that 
hydrogen bonding between the inhibitor and the binding site of the caspase greatly 
influences the inhibition capabilities of the inhibitor.  Accordingly, substituent groups 
with available electrons such as hydroxyl and methoxy groups could be used as possible 
groups on caspase inhibitors, contrary to prior belief.   
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OBJECTIVES 
Based on the previously stated research findings, the present project was to 
develop, synthesize and characterize caspase inhibitors using a combinatorial approach.  
As described earlier, SKB and the WashU group prepared a series of inhibitors using an 
isatin scaffold with two points of variability. While more recently the WashU group 
initiated studies on Michael acceptor based caspase inhibitors derived from such isatins, 
such inhibitors also possess just two sites of variability.  The goal of this project is to 
develop benzylidene oxindole derivatives bearing three sites of diversity as potential 
Michael acceptors for caspase inhibition.  A structural summary of the previous and 
proposed families of small molecule caspase inhibitors are shown below in Figure 9. 
N O
O
R2
R1
N O
R2
R1
CN
CN
N O
R2
R1
R3
SmithKline Beecham Washington Univ. St. Louis Wright State Univ.
 
Figure 9 
To synthesize such a combinatorial library of oxindole derived potential Michael 
acceptors for caspase inhibition, it was deemed necessary to develop a plan based on the 
functionalization and utilization of both oxindole and isatin derivatives (vide infra). The 
first step in the anticipated series of reactions would involve the addition of different 
functionalities to the C-5 position of these substrates.  To that end, the nitration of the C-5 
positions of isatin and oxindole were conducted, according to Schemes 2
13
 and Scheme 
3.
14 
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Scheme 2 
H2SO4/HNO3 at 0
0C for 1hr
N
H
O N
H
O
O2N
10 12  
Scheme 3 
H2SO4 at 0
0C for 1hr
H2SO4,  KNO3N
H
O
O
N
H
O
OO2N
7 13  
The nitration procedure follows an Electrophilic Aromatic Substitution (EAS) 
mechanism.
15  
In the EAS mechanism, sulfuric acid protonates nitric acid, giving off 
water as a byproduct and thereby generating the actual nitronium ion electrophile.  The 
EAS mechanism, which is the same mechanism followed for the nitrations of both 7 and 
10 is shown in Scheme 4. 
Scheme 4 
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Secondly, in place of the potentially reducible nitro group, a sulfonamide at the C-
5 position was desired.  To this end, both oxindole and isatin were treated with 
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chlorosulfonic acid to initially produce sulfonyl chloride derivatives, prior to treatment 
with the appropriate amines as shown in Scheme 5
16
 and Scheme 6
17
.  
Scheme 5 
N
H
O
HSO3Cl at 0
0C for 1hr
680C for 1hr
N
H
O
ClO2S
10 14  
Scheme 6 
HSO3Cl at 0
0C for 1hr
680C for 1hrN
H
O
O
N
H
O
OClO2S
7 15  
The necessity of functionalizing both oxindoles and isatins stems from the fact 
that oxindole cannot be alkylated regioselectively since it produces an ambident anion 
which affords a mixture of N-alkyl and 3-alkyl derivatives.  Thus, in order to secure N-
alkylated oxindoles before the aldol reactions necessary to produce benzylidene 
oxindoles, such alkylations must be performed at the isatin oxidation level. This N-
alkylation must be performed before the reduction of the C-3 carbonyl of 7 to the CH2.  
When the 5-substituted isatin is reduced to a 5-substituted oxindole, it will have two 
possible points of alkylation, the amide nitrogen and the α-carbon. Scheme 7 shows the 
possible outcomes of an alkylation reaction on 5-substituted oxindole.
18
  
Scheme 7 
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Thus, in order to secure N-alkylated oxindoles before the aldol reactions 
necessary to produce benzylidene oxindoles, such alkylations must be performed at the 
isatin oxidation level. Scheme 8 shows the process that will be used for the N-alkylation 
of isatin. Various alkyl groups will be used to determine the best possible combination of 
functional groups for optimum inhibition. 
Scheme 8 
 
 
 
 
 
 
 
Thus, upon C-5 functionalization, the oxindole can be treated directly with an 
aldehyde to afford the desired alkylidene oxindole, or if N-substitution is desired the 
corresponding N-alkylated isatin can be reduced to the oxindole by Wolff-Kishner 
reduction of the C-3 carbonyl using 80% hydrazine hydrate as the reducing agent.
19
 The 
reaction scheme is shown in Scheme 9. 
Scheme 9 
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This step will also be desirable due to the cost difference between isatin and 
oxindole.  Isatin is much cheaper than oxindole, making it the more affordable and the 
economical option for the experiments.  The mechanism
20
 for the Wolff-Kishner 
reduction is shown in Scheme 10.    
Scheme 10 
 
 
 
 
 
 
 
 
 
After reduction of the N,5-disubstituted isatin to an N,5-disubstituted oxindole, an 
aldol condensation is envisioned.  The aldol condensation
21
 is a reaction between an α-
carbanion and an aldehyde.  A weak base is used to abstract the α-H and the resulting 
enolate anion can then act as a nucleophile to attack the carbonyl of the aldehyde 
followed by a loss of water.  The mechanism for this reaction is shown in Scheme 11.
22 
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the double bond
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RESULTS AND DISCUSSION 
Initial attempts at securing 5-chlorosulfonylisatin involved heating isatin (7) in 
chlorosulfonic acid at 70 °C according to a literature procedure.
17
 However, the identity 
of this compound was recently called into question by the GSK
8
 group, who instead 
isolated a high yield of the gem-dichloro derivative (16b) as seen in Scheme 12. 
Scheme 12 
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 In our experiment, a melting point was performed on the product and it was found 
to be 137-140°C.  Isatin has a melting point of ~201°C, which provides evidence that the 
product is different from the starting material.  Unfortunately, the literature melting 
points for 5-chlorosulfonylisatin vary greatly, the earliest preparation in which the 
product was recrystallized from acetone-benzene was reported to have a melting point of 
150-152 
o
C,
17
 whereas more recent approaches involving treatment of 5-isatinsulfonic 
acid sodium salt with phosphorus oxychloride in tetramethylene sulfone reported a 
product with a melting point of 188-190 
o
C.
9
  Since we were unable to directly 
chlorosulfonate isatin, and in light of the recent commercial unavailability of 5-
isatinsulfonic acid sodium salt, it was decided to abandon further investigations into the 
study of sulfonamide isatins and their reduction to oxindoles. 
Attention was then focused on the N-alkylations of isatin using KF/alumina as a 
novel base and different alkylating agents.
23
 Whereas the literature protocols for N-
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alkylation normally involve the use of CaH2 in DMF solvent, the present protocol, 
employing acetonitrile as the solvent and KF/alumina as the base, would give an 
opportunity for a novel approach to this well studied N-alkylation reaction.  The reaction 
was performed according to Scheme 13 and the data associated with these experiments 
are shown in Table 2. 
Scheme 13 
 
 
 
Table 2: N-Alkylations of Isatin using KF/Alumina or CaH2  
 
Compound 
# 
 
Base 
 
R 
Experimental 
Melting Point 
(°C) 
Literature  
Melting 
Point (°C) 
 
% Yield 
 
 
17 
 
 
KF/alumina 
F
F
Br
 
 
 
178-185 
 
 
N/S* 
 
 
37.1  
 
18 
 
KF/alumina 
O
O
 
 
Liquid 
 
N/S 
 
N/A  
 
19 
 
KF/alumina 
O
O
Br  
 
190-197 
 
132-133
23 
 
 
Starting 
Material  
 
20 
 
KF/alumina 
Cl
 
 
196-199 
 
133-134
23
 
 
 
Starting 
Material  
 
21 
 
CaH2 
O
O
 
 
Liquid 
 
N/S 
 
24.9  
KF/Alumina
Acetonitrile
+ R-X
X=Cl, Br
N
H
O
O
N O
O
R
7 17-22
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22 
 
CaH2 
O
O
Br  
 
124-128 
 
132-133
23
 
 
 
38.3  
 
23 
 
CaH2 
Cl
 
 
134-139 
 
133-134
23
 
 
 
15.1  
*N/S= product has not been synthesized before in the literature. 
Unfortunately, the reactions performed were largely unsuccessful, with many of 
the reactions simply returning unreacted starting material, as proven by the melting points 
and their similarities to the melting point of 7.  The data presented in Table 2 indicates 
that N-alkylations using KF/alumina are not very promising.  The reactions performed to 
prepare compounds 18 and 21 involved attempted Michael type acceptors instead of alkyl 
halides.  For the preparation of compounds 22 and 23, the literature protocol involving 
CaH2 and DMF was used.  From Table 2, the experimental melting points and the 
literature melting points for compounds 22 and 23 are very similar, showing that the 
products are in fact the predicted ones, despite the fairly low yields.  Considering that the 
major goal of this research was the preparation of about 10 mg of a compound for 
screening, low yields were not considered an issue throughout this program of research 
because biological activity took priority over yield.  If the compound was screened and 
found biologically active, then further experimentation would be done to increase the 
overall yield.                         
 Having decided to abandon the C-5 sulfonamide moiety, the less desirable nitro 
group was then chosen as a representative EWG for our studies.  Thus, a nitration 
procedure was performed on isatin 7 and the melting point of the product was used to to 
compare it with the literature value published by SKB,
8
 as shown in Scheme 14.  
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Scheme 14  
H2SO4 at 0
0C for 1hr
H2SO4,  KNO3N
H
O
O
N
H
O
OO2N
7 13
 
Many of the procedures found in the literature for the nitration of 7 use fuming 
nitric acid,
24,25 
which was deemed undesirable due to lab safety considerations.  An 
alternate procedure was found which employs potassium nitrate and concentrated sulfuric 
acid.
14  
Using this procedure, a solution of potassium nitrate and sulfuric acid was first 
prepared and cooled to 0 
o
C in an ice bath.  A second solution of isatin and sulfuric acid 
was prepared and added dropwise to the aforementioned potassium nitrate solution over a 
period of 1 hr, making sure that the reaction temperature did not exceed 5 °C.  The 
reaction mixture was then poured over ice and the solid collected via vacuum filtration.  
The melting point of the product was 249-252 °C, which was very close to the literature 
melting point of 252-254 °C.
14
 Since this compound is known and had been shown by 
SKB to be active as a caspase inhibitor, a sample of 13 was sent to Dr. Thomas L. Brown 
for screening to compare the results using the Brown protocol to the SKB results. Since 
the N-alkylation reactions on 7 were not as successful and an N-methyl or N-benzyl 
derivative could not be produced, it was not expected that the N-unsubstituted isatin 13 
would be highly active, and in the event it was found inactive in the Brown protocol at 
concentrations of up to 100 M.  Additionally, it was also decided to test compounds 7 
and 10 to determine if any activity might be attributable to the scaffolds themselves, and 
expectedly they were found inactive.   
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Since at the moment it appeared that isatin derivatives with known activity were 
likely to show no activity in the Brown protocol, it was decided to focus on the 
benzylidene oxindoles described earlier by analogy to the Michael acceptor prepared by 
Dr. Edward Brush but with the potential for more sites of variability. Recalling that the 
SKB
8
 and WashU
10
 inhibitors had a maximum of two points of variability, the proposed 
benzylidene oxindoles have the advantage of having three readily accessible points of 
variability with the potential to tune potency and selectivity amongst various caspases.    
Deciding to employ oxindole as a potential scaffold for caspase inhibitors, a 
nitration procedure was then performed to add a –NO2 group at the C-5 position.  Even 
though this group is known to be reduced in vivo, it was decided to prepare some analogs 
bearing this functionality and if activity was found due to the presence of certain groups 
at the C-3 or N-position(s), another more suitable EWG at C-5 could be substituted. 
Therefore, compound 12 was prepared by nitration of 10 at 0 
o
C employing nitric acid/ 
sulfuric acid as shown in Scheme 15.
13
  
Scheme 15 
 
 
The product was recrystallized using a 50% acetic acid: water solution affording 
an overall yield of 85% after recrystallization.  The melting point was determined to be 
244-245°C which compares well with the literature melting point of 240-241°C, 
concluding that the product synthesized was indeed 12.
13
 Additionally, the formation of 
the product was confirmed by GC/MS and NMR spectroscopic analysis.  With the 
10
N
H
O
HNO3/H2SO4
0o C, 2.5 h
12
N
H
O
O2N
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oxindole bearing a strongly EWG at the C-5 position in hand, aldol condensations using 
several different aldehydes and 12 were then conducted to functionalize the C-3 position 
according to Scheme 16.   
Scheme 16 
 
 
 
In a typical procedure, a reaction mixture of 12 (1 equiv), aldehyde (1.2 equiv), 
and piperidine (0.1 equiv) in ethanol was stirred at 90 
o
C for 3-5 h.
21 
After the mixture 
cooled, the precipitate was filtered, washed with cold ethanol, and dried to give the target 
compounds. The aldehydes employed are shown in Table 3.   
Table 3: Aldol Condensations using 5-Nitroindolin-2-one 
 
Compound # 
 
R 
Experimental 
Melting Point 
(°C) 
Literature 
Melting Point 
(°C) 
E or Z 
Isomer 
Biological 
Activity 
 
24 
N
H  
 
>295 
 
308-310
32 
 
Z 
 
negative 
 
25 
Cl  
 
269-271 
 
N/S 
 
E 
 
N/T 
 
26 
F3C  
 
218-221 
 
N/S 
 
E:Z 
93:6 
 
negative 
 
27 
 
 
231-234 
 
N/S 
 
Z 
 
 
N/T 
N
H
O
Piperidine, Ethanol
Reflux 3 hr
+ R-CHO
N
H
O
RO2N O2N
12 24-29
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*N/T= product not tested for biological activity   *N/S= product has not been synthesized before in the literature 
The E:Z ratio of isomers in Table 3 were determined by GC/MS analysis.  Upon 
aldol condensation and spontaneous dehydration, the resultant benzylidene oxindoles can 
exist in either the E or Z conformation (or a mixture of both). The 
1
H NMR spectrum of 
each compound was examined very closely for subtle indicators that predict and confirm 
the configuration of each product.  The literature
26
 shows that the chemical shifts for the 
C-2‟ and the C-6‟ protons in the Z isomer are more downfield (7.85-8.53 ppm) than the 
C-2‟ and the C-6‟ protons in the E isomer (7.45-7.84 ppm).  In general, the C-2‟ and the 
C-6‟ (ortho) protons will be shifted downfield relative to the vinyl proton in the Z isomer, 
and the opposite is true for the E isomer.  The different structures for the E and Z isomers 
are shown in Figure 10.
27
 To determine if the products are accurately predicted, 
1
H and 
13
C NMR spectroscopic analyses were performed.  All of the spectra generated were 
analyzed and expanded using SpinWorks 3.1.   
 
 
 
 
 
 
28 
F
F
 
 
 
251-255 
 
 
N/S 
 
 
E 
 
 
negative 
 
 
29 
F
F
 
 
 
301-306 
 
 
N/S 
 
 
E:Z 
75:25 
 
 
negative 
 
31 
 
 
 
 
 
Figure 10 
There are several factors that can act to determine whether the compound will be 
predominantly in the E or the Z isomer.  Electrostatic interaction between the substituents 
on the C-3 benzylidene ring and the C-2 carbonyl will cause the ring to be in the Z 
isomer, while electrostatic repulsion will cause the ring to move into the E isomer form.
27
 
Also, hydrogen bonding between the substituents at the different positions on the C-3 
benzylidene ring and the C-2 carbonyl would also cause the products to favor the Z over 
the E configuration.
27
    
The compounds that were of most interest were those containing the 2,6-
difluorobenzaldehyde moiety, due to structural similarities to the Q-VD-OPh model 
inhibitor.  Compound 28, along with several other products from Table 3 were sent to 
our collaborator Dr. Thomas L. Brown for biological screening.  The biological assay is 
performed to verify whether the compound being tested inhibits apoptotic cell death or 
not.  The tests conducted were blind tests, meaning that the researchers doing the 
screening did not know what the compounds were; this eliminates any bias that may 
occur.  The screening was also done by different people at different times and all received 
the same results.  The gel for compound 28 is shown in Figure 11.      
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8  x 10
6
 cells/ml of Jurkat cells 
M- Marker 
V-Vehicle: 10µL DMSO + 10µL Methanol 
D- Drug only: 10µL 50mM 28 + 10µL Methanol 
AD- Actinomyocin D only: 10µL of 1µg/µL Actinomyocin D + 10µL DMSO 
20- 10µL of 20mM 28 + 10µL of 1µg/µL Actinomyocin D 
50- 10µL of 50mM 28 + 10µL of 1µg/µL Actinomyocin D 
100- 10µL of 100mM 28 + 10µL of 1µg/µL Actinomyocin D 
 
Figure 11 
The “M” channel is the DNA marker channel, which shows the DNA strands 
being tested.  The “V” channel contains the solvent and the cells being tested only and no 
compound 28.  The Drug (D) channel is compound 28 in methanol along with the cells 
being tested.  The “AD” channel contains cells that are treated with the Actinomycin D 
protein, which is a pro-apoptotic protein secreted from the mitochondria.  The channels 
that are marked with 20, 50 and 100 are the concentrations that the compound is being 
tested at.  The dark bands translate to inactivity, which also means the cells used for this 
assay, which were Human Jurkat T cells (Type 2 cells), underwent apoptotic cell death 
even at high concentrations (such as 100µM) of potential inhibitors.   
While it was deemed important to determine the relative inhibitory properties of 
compound 28 possessing the 2,6-difluorophenyl moiety resembling the warhead of Q-
VD-OPh, it was also thought interesting to examine the activity of compound 29 the 3,5-
M    V   D  AD 20  50  100  
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difluoro substitution pattern, as this was thought to enhance the Michael acceptor 
properties of the substrate.  Unfortunately, compound 29 proved insoluble under the 
screening conditions, so that proof of this hypothesis could not be achieved.  
O2N
N
H
O
F F
28
O2N
N
H
O
29
F F
 
It is also interesting to note that 5-nitroisatin (13) which was found active against 
caspase-3 by GSK, showed no activity in the WSU screen (gel not shown).  Although 
there are significant differences between the literature IC50 value and the value 
determined by the Brown protocol, this was determined inconsequential as we could 
establish a relative scale of activity for our compounds in any case.  
After a review of the screening results and careful interpretation of those results, a 
change in strategy was put into effect.  Since a –NO2 group demonstrated no clear 
advantage and could  be reduced to a toxic amine, it was decided to simply study the C-5 
unsubstituted oxindoles so as to determine the role of the group at C-3. Previously, Löser 
et al. had demonstrated that there was no need for an electrophilic functional group on the 
inhibitor for it to be active.
12
  It was then decided to perform aldol condensations on 
oxindole (10) using several different aromatic aldehydes with a range of electron 
withdrawing as well as electron donating substituents, especially those which might have 
available electron lone pairs for possible hydrogen bonding effects.  Thus, 3-substituted 
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indolin-2-ones were prepared by condensing indolin-2-one and aldehydes in the presence 
of a base.  Scheme 17 shows the reaction procedure used for the aldol condensations.
21
 
Scheme 17 
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The first procedure attempted used 10 equivalents of the base piperidine 
according to one literature procedure.
16
  Unfortunately, the yields for these reactions were 
very low at only ~20%.  The second procedure used to make the same compounds used 
only 0.1 equivalents (a catalytic amount) of piperidine and had much higher yields, 
approximately 80%.
21
  Several aldehydes were used following these procedures and their 
products are listed in Table 4. 
Table 4: Aldol Condensations using 5-Indolin-2-one and Aldehydes 
 
Compound 
# 
 
R 
Experimental 
Melting Point 
(°C) 
Literature 
Melting 
Point (°C)  
E or Z 
Isomer 
Biological 
Activity 
 
30 OH
 
 
298-301 
 
300+
28 
 
 
E 
 
negative 
 
31 N
 
 
226-229 
 
 
225-226
29
 
 
 
E:Z 
9:91 
 
active 
 
32 O
 
 
152-155 
 
155-156
18,30 
 
 
E:Z 
94:6 
 
active 
 
 
33 
F
F
 
 
 
213-218 
 
 
N/S 
 
 
E 
 
 
negative 
 
35 
 
*N/T= product not tested for biological activity    *N/S= product has not been synthesized before in the literature 
The E:Z ratio of isomers in Table 4 were determined by GC/MS analysis.  In 
assigning E or Z configuration to the compounds in the table above, the NMR analysis 
conducted on compound 30, which contains a hydroxyl functionality at the C-4‟ position 
on the C-3 benzylidene ring will be used as an example.  In the 
1
H NMR spectrum, the C-
2‟ and C-6‟ (ortho) protons are displayed as a doublet signal centered at 7.61 ppm while 
 
 
34 
F
F
 
 
 
202-205 
 
 
N/S 
 
 
E:Z 
92:8 
 
 
negative 
 
35 
Cl Cl
 
 
263-265 
 
N/S 
 
E:Z 
73:27 
 
N/T 
 
36 
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the vinyl proton appears as a singlet at 7.31 ppm.  Therefore, the ortho protons are further 
downfield than the vinyl proton, allowing assignment as the E configuration by the NMR 
considerations described earlier.  This 
1
H NMR spectrum analysis was applied to all of 
the compounds synthesized throughout this research to determine E or Z configurations.   
Several of the compounds synthesized in Table 4 were tested for biological 
activity, including compound 33 (possessing the 2,6-difluorophenyl moiety of Q-VD-
OPh),  the result of which is shown in Figure 12. The dark bands in the 10, 20, 50 and 
100 channels in Figure 12 show that compound 33 is inactive even at the highest 
concentration. 
 
 
 
 
 
 
 
1x 10
7
 cells/ml of Jurkat cells 
M- Marker 
V-Vehicle: 10µL DMSO + 10µL Methanol 
D- Drug only: 10µL of 50mM 33 +10µL Methanol 
AD- Actinomyocin D only: 10µL of 1ug/ µL Actinomyocin D + 10µL Methanol 
10- 10µL of 10mM 33 + 10µL of 1µg/µL Actinomyocin D 
20- 10µL of 20mM 33 + 10µL of 1µg/µL Actinomyocin D 
50- 10µL of 50mM 33 + 10µL of 1µg/µL Actinomyocin D 
100- 10µL of 100mM 33 + 10µL of 1µg/µL Actinomyocin D 
 
Figure 12 
 M   V    D   AD 10   20  50 100   
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  The structure for 33 was confirmed by 
1
H and 
13
C NMR spectroscopic analysis.  
To do this, the core structure (compound 10) was analyzed first using 
13
C NMR 
spectroscopy.  The 
13
C NMR Figure 13 shows eight signals that correspond to all eight 
carbons in 10. 
 
 
 
 
 
 
 
 
 
Figure 13 
The solvent signal, CDCl3, appears at ~77 ppm.  The C-2 amide carbonyl appears 
in the spectrum at 178.59 ppm.  The C-3 methylene signal appears in the aliphatic region 
at 36.39 ppm.  The aromatic region, approximately 110-150 ppm, contains six signals for 
the remaining six carbons on 10.  To distinguish the aromatic CH carbons from the 
quaternary carbons, a 
13
C DEPT 90 NMR spectrum was acquired on 10.  Quaternary 
carbons do not appear in any of the 
13
C DEPT subspectra, meaning that the spectra 
should only contain four signals in the aromatic region that correspond to the four 
aromatic CH‟s, which was the case.  The C-8 carbon appears further downfield at 142.84 
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ppm, due to its proximity to the amide nitrogen.  Also, the C-9 carbon is an aromatic, 
quaternary carbon.  When the 
13
C NMR of 10 is compared to the 
13
C DEPT 90 spectrum, 
a peak at 125.37 ppm disappears in the 
13
C DEPT 90 spectrum, meaning that the signal 
corresponds to the quaternary C-9 carbon.  The remaining four aromatic CH carbons are 
as follows; C-4 at 124.50 ppm, C-5 at 122.28 ppm, C-6 at 127.91 ppm and C-7 at 109.99 
ppm.  These values are consistent with the values stated in the literature.
33,34
  
After performing an aldol condensation reaction using 2,6-difluorobenzaldehyde, 
the product, (E)-3-(2,6-difluorobenzylidene)indolin-2-one (33), was also analyzed using 
13
C NMR spectroscopy, using the signals from 10 as the core scaffold.  Figure 14 shows 
the 
13
C NMR spectrum of 33.  
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Figure 14 
Based on the structure of the product, there are 13 different carbon atoms that 
correspond to the 13 signals observed.  The solvent used for this sample was DMSO-d6 
and that signal appears at ~39.5 ppm.  As can be seen from Figure 14, the C-2 carbonyl 
carbon has shifted upfield to 167.53 ppm.  The spectrum shows a very broad doublet of 
doublet peaks at ~161 and ~158 ppm, which correspond to carbons labeled C-12 and C-
12‟.  This broadening of the doublet peaks is due to the fluorine atoms, the first atom 
splitting the carbon spectrum to create a doublet while the second fluorine splits the 
spectrum again, creating a doublet of doublets.  The carbon labeled C-8 does not change 
position in the spectrum even after the reaction; it still appears at 143.23 ppm.  The C-3 
carbon, however, shifts dramatically downfield into the olefinic region, since it began as 
a methylene carbon and became a double bonded quaternary carbon, which now has a 
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signal at 132.29 ppm.  There is also a triplet signal centered at 131.93 ppm, which 
corresponds to the carbon labeled C-14.  The C-14 carbon is experiencing splitting by the 
fluorine atoms on the benzylidene ring, creating a triplet signal.   
The C-7 carbon remains relatively unchanged with a signal at 110.12 ppm in 
Figure 14.  Also, a signal appears at 120.70 ppm in the 
13
C NMR that does not appear in 
the 
13
C DEPT 90 NMR spectrum and this has been assigned to C-9 due to its quaternary 
nature and its aromaticity, which is fairly close to the oxindole value.  The 
13
C DEPT 90 
NMR spectrum shows the CH peaks that are in the aromatic region.  The carbons from 
the original structure of 10 in Figure 13 are relatively in the same position, with the C-4 
signal showing at 121.46 ppm, the C-5 signal appearing at 119.71 ppm and the C-6 
carbon signal emerging at 130.80 ppm.  The carbon labeled C-10 is a CH carbon which 
appears in both spectra as a triplet at 123.09 ppm.  This splitting of the C-10 signal is also 
due to its proximity to the fluorine atoms.  Further, the C-11 signal is split into a triplet 
and is overlapped within the C-12 and C-12‟ signal, with its center peak showing at ~112 
ppm.   
It was very discouraging to see that compound 33 was inactive, since the initial 
expectation had been that the difluorophenyl group from Q-VD-OPh would be a 
successful addition to the active inhibitor library.  The active compound X though, was 
created by pure accident.  Originally, using compound 33 as the starting material, it was 
decided to nitrate the compound assuming that addition of the nitro group would occur 
exclusively or predominantly at the C-5 position although there was no literature 
precedent.
13
 Scheme 18 shows the reaction performed on 33 and the predicted product.  
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Scheme 18    
 
 
 
If the nitration had occurred on the C-5 position, then compound 28 would be the 
final product.  However, the product obtained from the nitration of benzylidene oxindole 
demonstrated significant cell death inhibition.  From the data in Table 3, the expected 
product 28 demonstrated no inhibition of cell death, it was therefore assumed that 28 
could not be the nitrated compound obtained, and that nitration had occurred elsewhere 
on the molecule, perhaps even on the difluorophenyl ring. The reaction and its possible 
product(s) are shown in Scheme 19.  Moreover, there is a mysterious byproduct that 
forms during this procedure that has a molecular weight of 282 m/z by GC/MS analysis, 
while the starting material 33 has a molecular weight of 257 m/z.  Therefore, there is only 
one nitro group adding to the compound, giving it a total molecular weight of 302 m/z.  In 
the case of the byproduct, the mass difference from the expected product indicates a 
possible loss of a fluorine atom perhaps by some nucleophilic aromatic substitution 
process. The initial screen involved testing of a sample consisting of approximately equal 
amounts of X and its defluorinated byproduct. Although it was not common practice to 
screen impure mixtures, failed initial attempts to purify the sample and in the interests of 
time, an answer as to the potency of the 2,6-difluorophenyl group was needed and if it 
were highly active, even a mixture would demonstrate cell death inhibition. 
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Scheme 19  
 
 
 
 
The biological assay performed on compound X is shown in Figure 15.  As can 
be seen in Figure 15, compound X was 100% active at 100 µM and about 50% active at 
50 µM, even in its impure state.  
 
 
8.45 x 10
6
 cells/ml of Jurkat cells 
M- Marker 
V-Vehicle: 10µL DMSO 
F- α Fas only: 2µL of α Fas (clone C-11) 100ng/mL[Final] + 10µL DMSO 
20- 10µL of 20mM X+ 2µL of α Fas (clone C-11) 100ng/mL[Final] 
50- 10µL of 50mM X + 2µL of α Fas (clone C-11) 100ng/mL[Final] 
100- 10µL of 100mM X + 2µL of α Fas (clone C-11) 100ng/mL[Final] 
 
Figure 15 
Subsequent to this initial screening result, column chromatography was employed 
to separate the unwanted byproduct and to afford progressively pure compound X (MW = 
302).  This was a very long and tedious process because the active compound and its 
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byproduct are very similar in polarity by TLC.  Figure 16 shows the gel performed on a 
more purified version of compound X.  It is seen from Figure 16 that the compound was 
100% active at 20 µM concentration. 
 
 
6.4x 10
6
 cells/ml of Jurkat cells 
M- Marker 
V-Vehicle: 10µL of DMSO & 10µL of Methanol 
D- Drug: 25µL Q-VD-OPh 
AD- 10µL of AD 
20- 10µL of X & 10µL of AD 
50- 25µL of X & 10µL of AD 
100- 50µL of X & 10µL of AD 
 
Figure 16 
Several methods were used to purify compound X, including prep TLC, liquid 
chromatography and standard column chromatography.  Finally, after several purification 
procedures, compound X was isolated and shown to be pure by GC/MS analysis and 
1
H 
and 
13
C NMR spectral analyses.  Figure 17 shows the gel performed on the purest form 
of compound X.   
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1.28 x 10
6
 cells/ml of Jurkat cells 
M- Marker 
AD- Actinomyocin D only: 10µL of 1µg/µL Actinomyocin D + 10µL Methanol 
5- 10µL of 5mM X + 10µl of 1µg/µL Actinomyocin D 
10- 10µL of 10mM X + 10µl of 1µg/µL Actinomyocin D 
20- 10µL of 20mM X + 10µl of 1µg/µL Actinomyocin D 
 
Figure 17 
Pure X was active at an astonishingly low concentration of 5 µM.  This was a 
very promising result, since the commercially available Q-VD-OPh is also active at 5 
µM.
5
  It was also important to determine whether compound X was inhibiting apoptosis 
via caspases or not, and/or which caspase it was actually inhibiting.  To do this, 
compound X was tested against other cysteine proteases.  Cathepsins, which are cysteine 
proteases as well, are also responsible for carrying out apoptosis.
35
  Cathepsins are 
synthesized in the lysosome of the cell as inactive enzymes called zymogens and are 
released when an intrinsic or extrinsic cell death signal is given.
35
 The test against 
cathepsin L, which is the most common cathepsin secreted upon distress, was done by 
Dr. Scott Diamond and Dr. Tianhua from the University of Pennsylvania‟s Institute for 
Medicine and Engineering in Philadelphia, Pennsylvania.  The testing was done on a 
blind basis, meaning that the personnel doing the testing did not know what the 
compounds were and that the compounds are tested twice for comparison purposes.  The 
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compounds that were tested were compound X and compound 33.  For compound X, the 
result was an IC50 of 43µM against cathepsin L, which means that compound X is not a 
very active inhibitor of cathepsin L. Compound 33 tested negative.  
Testing was also done against another class of cysteine proteases called calpains, 
which are also involved in signaling for apoptosis.
36,37
 Calpains are activated when there 
is an increase in the Ca
2+
 ion concentration in the cytosol of the cell.
37
 The calpain testing 
was done by Dr. Andrew Abell and Dr. Ondrej Zvarec from the School of Chemistry and 
Physics at The University of Adelaide in Adelaide, Australia.  The testing was also done 
blindly and they too tested compounds 33 and X.  The results from the calpain test show 
an IC50 of 3.3µM calpain inhibition for compound X, meaning that it is an average 
calpain inhibitor.  The results from these two tests show that compound X is an average 
inhibitor of cathepsins and calpains.  This is promising because for compound X to be 
caspase specific, it cannot be very active against other cysteine proteases.  This would 
make it non-specific and therefore non-usable as a drug.  The experiment that has yet to 
be done is to test compound X against the different caspases to see which one it is 
actually inhibiting and by which pathway.  
Now that the inhibition activity was shown to be very effective, it was necessary 
to determine the actual structure of the inhibitor X.  There were two possible areas that 
the nitro group would be expected to attack, the C-3 benzylidene ring or the aromatic 
portion of the heterocyclic oxindole ring.  To determine the carbon most likely to be 
attacked by the electrophilic nitronium ion, ChemDraw Ultra was used to predict the 
13
C 
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NMR shifts of the starting material 33.  Figure 18 shows the ChemDraw predictions of 
the 
13
C NMR shifts of 33.     
 
 
 
 
 
 
Figure 18 
The carbon with the lowest value (ppm) will be the most likely place of nitration, 
being the most electron rich site on the compound.  From Figure 18, the carbon with the 
highest electron density would be ortho to the fluorines on the C-3 benzylidene ring.  
This makes sense because fluorines are electronegative and will pull electron density 
away from the adjacent carbons and towards themselves by inductive effects, but are 
reasonably strong electron donors via resonance.  With that in mind, an alternate 
synthesis was planned.  The original procedure from Scheme 19 was a very tedious 
procedure and an unwanted byproduct was formed every time the synthesis was 
performed.  Scheme 20 and Scheme 21 show the new synthetic path expected to form 
compound X.  Thus, 2,6-difluorobenzaldehyde (41) was nitrated using  a literature 
procedure as shown in Scheme 20.
38
  The product 42 was then condensed to 10 by an 
aldol condensation to afford 43 as shown in Scheme 21. 
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Scheme 20 
 
 
 
Scheme 21 
 
 
 
 
Compound 42 was synthesized with relative ease and a yield of 17%.  The 
reaction from Scheme 21 gave product 43 with a yield of 12%.  Product 43 was pure by 
TLC and GC/MS analysis did not show any signs of the 282 m/z byproduct that had been 
formed in the previous synthesis.  The structure of compound 43 was confirmed by 
GC/MS and 
13
C NMR spectroscopic analyses.  The 
13
C NMR spectrum for compound 43 
is shown in Figure 19. 
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Figure 19 
The 
13
C NMR spectrum of 43 is different from the 
13
C NMR of compound X, 
which raised some concern as to whether this compound was in fact the active compound 
X.  In Figure 19, there are 15 signals that correspond to all of the signals in the structure 
of compound 43.  All of the signals in Figure 19 are singlet peaks, while in the spectrum 
of compound X (not shown), the signals are experiencing different splitting patterns into 
doublets and triplets.  There is also a difference in the number of signals between the two 
compounds 43 and X, which is a definitive indicator that the compounds are not the 
same.  To determine whether compound 43 is active or not, a sample of it was sent to Dr. 
Brown for biological screening.  The gel for compound 43 is shown in Figure 20.  The 
compound had tested negative, even at 100 µM.  
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7.0 x 10
6
 cells/ml of Jurkat cells 
M- Marker 
V-Vehicle: 20µL DMSO & 10µL CH3OH 
AD- Actinomycin D: 10µL AD 
20- 4µL of 43 & 10µL AD 
50- 10µL of 43 & 10µL AD 
100- 20µL of 43 & 10µL AD 
 
Figure 20 
At this point, a pressing question arose as to what might be the actual structure of 
active compound X?  Obviously the ChemDraw prediction of relative electron density of 
compound 33 (Figure 18) which indicated the most likely site of nitration was ortho to 
the fluorines was not correct otherwise compound 43 would have been active.  It was 
then decided to take a closer look at the 
13
C NMR spectra of the precursor 10 of the 
active compound X.  An examination of the spectra of 10 (Figure 13), indicates that the 
carbon with the highest electron density is C-7, which has a signal at 109.99 ppm; a value 
which is consistent with the literature assignment.
34
 Moreover, after a reaction with 2,6-
difluorobenzaldehyde to form compound 33, C-7 is still the most electron rich carbon 
with its signal at 110.12 ppm as shown in Figure 14.  For comparison, the carbons 
adjacent to the fluorines, C-12 and C-12‟are a doublet peak centered at ~112 ppm 
indicating that C-7 is the most electron rich carbon in compound 33.  Based on this 
interpretation of the 
13
C NMR spectrum, the point of nitration on compound 33 would 
 
50 
 
most likely be C-7 and not C-12 or C-12‟.  To prove or disprove this theory, it was 
necessary to either prepare or purchase 7-nitrooxindole (45) and conduct its reaction with 
33.  Purchasing 45 was economically prohibitive, since it is a custom synthetic 
compound.  Examination of  the literature revealed a procedure to synthesize 45 from 8-
nitroquinoline (44).
39,40,41
  The procedure involves using 30% H2O2 and acetic acid to 
oxidize 44 to form 45 through a proposed lactone intermediate.
42
  This reaction procedure 
is shown in Scheme 22.         
Scheme 22  
 
 
 
This reaction was performed under moderate conditions with relative ease.  The 
yield of compound 45 was 14%, which was comparable to the literature yield of 20%.
42
 
Using 45 as the starting material, an aldol condensation was performed using 41 to form 
46.  This procedure is shown in Scheme 23.   
Scheme 23   
 
 
 
 
Reviewing again, compound 46 was synthesized due to its likelihood of being the 
actual active compound X based on a consideration of the electron density at C-7 based 
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on 
13
C NMR shifts.  Unfortunately the results of the biological activity were not available 
by the time of the thesis defense. 
While the initial goal of this project was to employ some of the structural features 
of Q-VD-OPh, the difficulties presented by the use of the 2,6-difluorophenyl substituent 
in terms of the defluorinated byproduct led us to examine a number of other possible aryl 
aldehydes in search of activity.  In this regard, it is interesting to note that a 4-methoxy 
group on the aryl ring at the C-3 position demonstrated a low level of activity. This is 
noteworthy since our working hypothesis entailed nucleophilic attack by the cysteine 
residue of caspases on the -carbon of the benzylidene oxindoles and a para-methoxy 
would be expected to reduce the electrophilicity of this position. Thus, the marginal 
activity of compound 32 (~50µM) came as somewhat of a surprise.  The gel for active 
compound 32 is shown in Figure 21.  The fact that this compound demonstrates may thus 
be an example of the non-electrophilic type of warhead suggested by Löser et al.
12
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4 x 10
6
 cells/ml of Jurkat cells  
M- Marker 
V-Vehicle: 20µL DMSO & 10µL Methanol 
D- Drug: 20 µL of 32 
AD- 10 µL AD 
20- 4µL of 32 & 10µL AD 
50- 10µL of 32 & 10µL AD 
100- 20µL of 32 & 10µL AD  
 
Figure 21 
 
The 
13
C NMR spectrum of compound 32 is shown in Figure 22.  
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Figure 22 
The product 32 was confirmed by 
1
H and 
13
C NMR spectroscopic analysis. 
Figure 22 shows 14 signals in the 
13
C NMR NMR that correspond to the structure for 
active compound 32.  The solvent used for this spectrum was DMSO-d6, which appears at 
~39.5 ppm.  As can be seen, there is a peak in the aliphatic region at 55.26 ppm, which 
corresponds to the CH3 of the methoxy group on C-15 while the C-2 amide carbonyl 
appears at 168.93 ppm.  Also, the aromatic carbon bearing the methoxy group appears 
downfield with a signal at 160.48 ppm.  Further examination of the other peaks in the 
aromatic region utilized 
13
C DEPT 90 NMR to distinguish between the CH aromatic 
carbons and the quaternary aromatic carbons.  The signal at 142.65 ppm appears in the 
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13
C NMR spectrum but not in the 
13
C DEPT 90, meaning that it corresponds to the 
quaternary carbon labeled C-8.  The signal at 135.94 ppm is present in both spectra, 
meaning that it is an aromatic CH carbon that corresponds to C-10.  There are two intense 
signals that are also present in both spectra.  They appear at 131.42 ppm and 114.17 ppm.  
The first signal can be identified as C-12 and C-12‟ as they are symmetrical CH carbons 
and the second signal is identified as C-13 and C-13‟ as they too are symmetrical 
carbons.   
The original CH carbons on 10 do not shift very much from their original 
positions: C-4 at 122.02 ppm, C-5 at 120.95 ppm, C-6 at 129.58 ppm and C-7 at 109.98 
ppm.  The remaining quaternary aromatic carbons have lower intensity signals and are 
not visible in the 
13
C DEPT 90 NMR.  These are carbons C-3, C-9 and C-11.  Carbon C-3 
has a signal at 121.17 ppm, which is a dramatic shift downfield from the original 
oxindole (10) C-3 carbon.  Carbon C-9 does not shift very much from its original position 
in 10, with its signal at 125.61 ppm.  The C-11 carbon signal is very close to C-9 with its 
signal showing at 126.59 ppm.   
  Finally, the third active compound might in some way be considered as 
mimicking the structural features of Q-VD-OPh in that it incorporates a pyridine ring 
which resembles the quinoline ring of the peptide inhibitor.  Compound 31, which has a 
nitrogen atom with an available lone pair of electrons at the C-4‟ position was found 
active at ~20 µM concentration.  Hydrogen bonding between 31 and the active site on the 
caspase could be the mechanism of action of this non-electrophilic inhibitor.  The gel for 
compound 31 is shown in Figure 23.   
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4.4 x 10
6
 cells/ml of Jurkat cells  
M- Marker 
V-Vehicle: 20µL DMSO & 10µL CH3OH 
D- 20µL of 31 
AD- Actinomycin D: 10 µL AD 
20- 4µL of 31 & 10µL AD 
50- 10µL of 31 & 10µL AD 
100- 20µL of 31 & 10µL AD 
 
Figure 23 
The structure for compound 31 could not be determined definitively by 
13
C NMR 
spectroscopy due to it being a mixture of the E and Z configurations.  The major isomer 
was determined by the melting point and its proximity to either of the two isomer‟s 
literature melting points.
29
  Both the 
13
C and 
1
H NMR spectra have double the amount of 
signals expected for compound 31.   
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FUTURE WORK 
 There is still a lot of work to be done to be able to say that an active and effective 
caspase inhibitor has been synthesized.  More derivatives of the active compounds X, 31 
and 32 need to be made to optimize the groups at the different positions and maximize 
inhibition capabilities.  Hopefully compound X, once it is fully characterized and the 
synthesis is solid and repeatable with good yields, can be taken even further than just in 
vitro testing.  I would like to see it tested on small animals and from there, go into clinical 
trials if it is safe and effective.  As of now, I believe that my work has led to new ideas 
and new leads to pursue further.  Beginning a project that no one has done before and 
achieving three active compounds in two years I believe is an accomplishment. 
 I would also like to see these active compounds tested against other apoptotic 
mechanisms.  In this work, the testing was done against Human Jurkat T cells (Type 2 
cells) by Dr. Thomas L. Brown.  Testing these compounds against other apoptotic cells 
that may not be as common or as well known, such as retinal cells (in the eye) would be 
interesting to study.  Retinal cell death is an area where small molecule apoptotic 
inhibitors have not been studied before, so it would broaden the scope of the use of these 
small molecule inhibitors as well.   
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EXPERIMENTAL 
Chemical Analysis  
Melting points were determined via the use of open capillaries with an Electrothermal 
melting point apparatus and are reported uncorrected.  Elemental analyses were 
performed by Midwest Microlab, Indianapolis, IN.  Elemental analysis results are within 
+0.4% of the theoretical values. The 
1
H and 
13
C NMR data were obtained on a Bruker 
Avance 300 MHz NMR in CDCl3 solution unless otherwise indicated.  The chemical 
shifts are reported in δ (ppm) downfield from tetramethylsilane as an internal standard; 
coupling constants (J) are in Hz.  The following abbreviations are used to describe peak 
patterns where appropriate: s, singlet; d, doublet, dd, double doublet; t, triplet; q, quartet; 
dt, double triplet; m, multiplet.  GC/MS measurements were performed using Hewlett-
Packard 6890 Series GC with auto injection and mass fragments are reported as mass per 
charge, m/z.  The GC was coupled with a mass spectrometer with a Hewlett-Packard 
5973 mass selective detector/quadrupole system. Flash column (Silica Gel, Premium Rf, 
200-400 mesh, Sorbent Technologies) and thin layer chromatography (TLC) were 
performed on silica gel with indicated solvent systems.  All glassware and syringes were 
oven-dried for the reactions which require anhydrous conditions.  The multimode 
microwave used for solventless reactions on silica gel was a GE JES638WF 700 Watt 
domestic microwave with a turn table with time and power controls.  All microwave 
reactions were performed in a monomode Biotage Emery‟s Creator 300 Watt system and 
the MARS Glasschem 300 Watt system by CEM.  It should be noted that all reactions 
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were run with sample absorption set to “normal”.  Multiple reactions were carried out 
using the FIRSTMATE system by Argonaut Technologies.  
 
Biological Analysis 
Human Jurkat T cells were treated with vehicle (V) or 1 mg/ml actinomycin D for four 
hours.  DNA was isolated, and analyzed on a 1.2% agarose gel stained with ethidium 
bromide to determine DNA laddering.  The agarose gel showed 50% functionality at 100 
mm, resulting well below the inhibitory effects at 200 mm.  Cytoplasmic DNA is small 
(less than 1500 bp) and is generated in apoptotic cells and can cross the nuclear 
membrane into the cytosol.  If concentrations of the DNA are less than 200 mm, then cell 
inhibition is not justified.  
 
5-Nitroindolin-2-one (12)  
To a 25-mL Erlenmeyer flask in an ice bath containing sulfuric acid (1.9231 mL) and 10 
(0.5121 g, 0.0038 mol) was added  nitric acid (0.1615 mL) drop-wise with stirring.  The 
mixture was stirred for 30 min after which the mixture was poured over ice.  A brown 
colored solid (0.6030 g) was collected via vacuum filtration. Recrystallization using 50% 
acetic acid: water gave the pure product (beige color) (0.5621 g, 82%); mp 244-245 
o
C 
(lit. mp 240-241
 o
C)
13
; Rf = 0.55 (EtOAc); 
1
H NMR (300 MHz, DMSO-d6) 11.05 (s, 
1H) 8.15 (d, J = 8.6 Hz, 1H), 8.09 (s, 1H), 6.97 (d, J = 8.6 Hz, 1H), 3.63 (s, 2H); 
13
C 
NMR : 176.65, 150.24, 141.69, 127.00, 124.86, 119.95, 108.92, 35.56 ppm. 
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5-Nitroindoline-2,3-dione (13)   
A solution of 7 (0.5 g, 3.4 mmol) in concentrated sulfuric acid (3.2 mL) was added 
dropwise to a solution of potassium nitrate (0.344 g, 3.4 mmol) in concentrated sulfuric 
acid (3.8 mL) in a 25-mL Erlenmeyer flask over a period of 1 h in an ice bath.  The 
reaction mixture was poured over ice.  The yellow-orange solid was collected via vacuum 
filtration (0.441 g, 67.5%). mp = 249-252°C (lit mp = 252-254 °C)
14
; Rf = 0.71 (EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  11.67 (s, 1H), 8.45 (d, J = 8.71 Hz, 1H), 8.22 (s, 1H), 
7.10 (d, J = 8.72 Hz, 1H)     
 
1-(2,6-Difluorobenzyl)indoline-2,3-dione (17) 
In a vial with acetonitrile (3 mL) was dissolved isatin (0.3 g, 0.00204 mol) and 
KF/Alumina (1 equiv, 0.1185 g, 0.00204 mol).  2,6-Difluorobenzyl bromide (2 equiv, 
0.8446 g, 0.00408 mol) was added to the vial.  The vial was placed on a 30 °C hot plate 
for 5 days.  The vial was then heated at 50 °C for 48 h.  Deionized water was added to the 
vial and stirred for 6 days at room temperature.  Bright orange solid was collected via 
vacuum filtration (0.2066 g, 37.1 %). mp = 178-185
 o
C; Rf = 0.89 (EtOAc); 
1
H NMR 
(300 MHz, DMSO-d6) 7.60 (d, J = 6.60 Hz, 1H), 7.53 (dt, J = 7.82 Hz, 1H), 7.36-7.27 
(m, 1H), 7.31 (t, J = 6.55 Hz), 7.10 (t, J = 7.35 Hz, 1H), 6.94 (t, J = 8.20 Hz, 1H), 5.03, 
(s, 1H). 
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Attempted Synthesis of (18) 
In a vial with acetonitrile (3 mL) was dissolved 7 (0.3 g, 0.00204 mol) and KF/Alumina 
(1 equiv, 0.1185 g, 0.00204 mol).  Ethyl acrylate (2 equiv, 0.4085 g, 0.00408 mol) was 
added to the vial.  The vial was placed on a 30°C hot plate for 5 days.  The vial was then 
heated at 50 °C for 48 hrs.  Deionized water was added to the vial and stirred for 6 days 
at room temperature.  The product was an oily substance. The synthesis yielded only 
starting material based on the melting point. 
 
Attempted Synthesis of (19) 
In a vial with acetonitrile (3 mL) was dissolved 7 (0.3 g, 0.00204 mol) and KF/Alumina 
(1 equiv, 0.1185 g, 0.00204 mol).  Ethyl bromoacetate (2 equiv, 0.6814 g, 0.00408 mol) 
was added to the vial.  The vial was placed on a 30°C hot plate for 5 days.  The vial was 
then heated at 50 °C for 48 hrs.  Deionized water was added to the vial and stirred for 6 
days at room temperature.  The product was an oily substance (0.2168 g, 45.6 %).  mp = 
190-197
 o
C (lit mp = 132-133 °C)
23
; Rf = 0.83 (EtOAc). The synthesis yielded only 
starting material based on the melting point. 
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Attempted Synthesis of (20) 
In a vial with acetonitrile (3 mL) was dissolved 7 (0.3 g, 0.00204 mol) and KF/Alumina 
(1 equiv, 0.1185 g, 0.00204 mol).  Benzyl chloride (2 equiv, 0.5165 g, 0.00408 mol) was 
added to the vial.  The vial was placed on a 30°C hot plate for 5 days.  The vial was then 
heated at 50 °C for 48 hrs.  Deionized water was added to the vial and stirred for 6 days 
at room temperature.  The product (bright orange) was collected by vacuum filtration 
(0.2251 g, 46.5 %). mp = 196-199
 o
C (lit mp = 133-134 °C)
23
; Rf = 0.63 (EtOAc). The 
synthesis yielded only starting material based on the melting point. 
 
tert-Butyl 3-(2,3-dioxoindolin-1-yl)propanoate (21)   
In a vial with acetonitrile (3 mL) was dissolved 7 (0.3 g, 0.00204 mol) and KF/Alumina 
(1 equiv, 0.1185 g, 0.00204 mol).  t-Butyl acrylate (2 equiv, 0.5229 g, 0.00408 mol) was 
added to the vial.  The vial was placed on a 30 °C hot plate for 5 days.  The vial was then 
heated at 50 °C for 48 h.  Deionized water was added to the vial and stirred for 6 days at 
room temperature.   A silica gel column was performed using 70:30 Hexanes: EtOAc to 
afford an orange- red oil. (0.14 g, 24.9%) mp = N/A; Rf = 0.83 (EtOAc); 
1
H NMR (300 
MHz, DMSO-d6)  7.68 (t, J = 15.6 Hz, 1H), 7.56 (d, J = 7.41 Hz, 1H), 7.25 (d, J = 7.96 
Hz, 1H), 7.14 (t, J = 15.0 Hz, 1H), 3.89 (t, J = 14.1 Hz, 2H), 2.60 (t, J = 14.1 Hz, 2H), 
1.35 (s, 3H).  
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Ethyl 2-(2,3-dioxoindolin-1-yl)acetate (22)    
Compound 7 (2 g, 13.6 mmol) and CaH2 (1 equiv, 0.5720 g, 13.6 mmol) were dissolved 
in DMF (6.61 g) in a vial and stirred at 100°C for 1 h.  The solution was cooled to 40°C 
so that ethyl bromoacetate (3 equiv, 6.812 g, 40.8 mmol) could be added to the vial.  The 
vial was placed back on the hot plate at 100°C for 4h then cooled to room temp.  The 
solution was poured into an aqueous solution of 0.5 M HCl (40 mL) stirring vigorously.  
Orange precipitate was collected via vacuum filtration.  Product was recrystallized using 
a 50% DCM/hexanes solution to afford a yellow product (1.2139 g, 38.3%).  mp = 124-
128°C (lit mp = 132-133 °C)
23
; Rf = 0.70 (EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  
7.69 (t, J = 15.5 Hz, 1H), 7.62 (d, J = 7.39 Hz, 1H), 7.19 (t, J = 16.6 Hz, 1H), 4.63 (s, 
2H), 4.18 (q, J = 14.17 Hz, J = 7.07 Hz,  2H), 1.22 (t, J = 14.2 Hz, 3H) 
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1-Benzylindoline-2,3-dione (23)     
Compound 7 (2 g, 13.6 mmol) and CaH2 (1 equiv, 0.5720 g, 13.6 mmol) were dissolved 
in DMF (6.61 g) in a vial and stirred at 100°C for 1 h.  The solution was cooled to 40°C 
so that benzyl chloride (3 equiv, 5.165 g, 40.8 mmol) could be added to the vial.  The vial 
was placed back on the hot plate at 100°C for 4h then cooled to room temp.  The solution 
was poured into an aqueous solution of 0.5 M HCl (40 mL) stirring vigorously.  Red 
precipitate was collected via vacuum filtration.  Product was recrystallized using a 50% 
DCM/hexanes solution to afford an orange product (0.486 g, 15.1%).  mp = 134-139°C 
(lit mp = 133-134 °C)
23
; Rf = 0.86 (EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  7.66 (d, J 
= 7.31 Hz, 1H), 7.57 (d, J = 6.65 Hz, 1H), 7.21 (t, J = 14.1 Hz, 1H), 6.98 (d, J = 8.18 Hz, 
1H), 6.72 (t, J = 17.9 Hz, 1H), 6.57 (t, J = 14.7 Hz, 1H), 6.50 (t, J = 14.9 Hz, 1H), 4.91 
(s, 2H).  
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(Z)-3-((1H-pyrrol-2-yl)methylene)-5-nitroindolin-2-one (24)   
In a FIRSTMATE reaction tube with a stir bar was combined 12 (0.3385 g, 0.0019 mol) 
with pyrrole-2-carboxaldehyde (1.2 equiv, 0.2161 g, 0.00228 mol) and piperidine (0.10 
equiv, 0.0194 g, 0.000228 mol) and EtOH (2 mL).  The reaction tube was placed in the 
holder and the system was set to the following parameters: interval = 5, up stroke = 4, 
speed = max, hot plate temp = 90 °C, time = 3 h and inert gas = Argon. Reddish-brown 
solid (0.4658 g, 96.1%) was collected via vacuum filtration: mp = >295 °C (lit mp = 308-
310 °C)
32
; Rf = 0.77 (EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  11.49 (s, 1H), 8.53 (d, J 
= 2.17 Hz, 1H), 8.09 (s, 1H, Hvinyl), 8.04 (dd, J = 8.61 and  2.23 Hz,  1H), 7.44 (s, 1H), 
7.01 (d, J = 8.61 Hz, 1H), 6.41 (dd, J = 5.8 and 2.24 Hz, 1H).      
 
(E)-3-(2-chlorobenzylidene)-5-nitroindolin-2-one (25)    
In a FIRSTMATE reaction tube with a stir bar was combined 12 (0.3385 g, 0.0019 mol) 
with 2-chlorobenzaldehyde (1.2 equiv, 0.3258 g, 0.00228 mol) and piperidine (0.10 
equiv, 0.0194 g, 0.000228 mol) and EtOH (2 mL).  The reaction tube was placed in the 
holder and the system was set to the following parameters: interval = 5, up stroke = 4, 
speed = max, hot plate temp = 90 °C, time = 3 h and inert gas = Argon. Green-yellow 
solid (0.1148 g, 20.1%) was collected via vacuum filtration: mp = 269-271 °C; Rf = 0.74 
(EtOAc); Compound 25 would not dissolve in any of the deuterated NMR solvents, 
therefore an NMR spectrum could not be generated. 
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(E)-3-(2-(trifluoromethyl)benzylidene)-5-nitroindolin-2-one (26)   
In a FIRSTMATE reaction tube with a stir bar was combined 12 (0.3385 g, 0.0019 mol) 
with trifluoro-o-tolualdehyde (1.2 equiv, 0.4151 g, 0.00228 mol) and piperidine (0.10 
equiv, 0.0194 g, 0.000228 mol) and EtOH (2 mL).  The reaction tube was placed in the 
holder and the system was set to the following parameters: interval = 5, up stroke = 4, 
speed = max, hot plate temp = 90 °C, time = 3 h and inert gas = Argon. Yellow solid 
(0.2922 g, 46.0%) was collected via vacuum filtration: mp = 218-221 °C; Rf = 0.75 
(EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  11.46 (s, 1H), 7.97 (d, J = 7.59 Hz, 1H), 7.90 
(s, 1H), 7.86 (s, 3H), 7.83-7.78 (m, 1H), 7.60 (s, 1H, Hvinyl), 7.06 (d, J = 8.69 Hz, 1H, C-
6‟).    
 
(Z)-3-(3-methylbutylidene)-5-nitroindolin-2-one (27)   
In a FIRSTMATE reaction tube with a stir bar was combined 12 (0.3385 g, 0.0019 mol) 
with isovaleraldehyde (1.2 equiv, 0.2205 g, 0.00228 mol) and piperidine (0.10 equiv, 
0.0194 g, 0.000228 mol) and EtOH (2 mL).  The reaction tube was placed in the holder 
and the system was set to the following parameters: interval = 5, up stroke = 4, speed = 
max, hot plate temp = 90 °C, time = 3 h and inert gas = Argon. Off-white solid (0.2894 g, 
61.9%) was collected via vacuum filtration: mp = 231-234 °C; Rf = 0.68 (EtOAc); 
1
H 
NMR (300 MHz, DMSO-d6) 10.80 (s, 1H), 7.77 (s, 1H, Hvinyl), 6.86 (d, J = 8.66 Hz, 
1H), 6.60 (d, J = 11.18 Hz, 1H), 6.40 (d, J = 7.46 Hz, 2H), 3.70 (d, J = 11.73 Hz, 2H), 
1.85-1.53 (m, 1H), 1.18 (s, 3H).      
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(E)-3-(2,6-difluorobenzylidene)-5-nitroindolin-2-one (28)     
In a vial was combined 12 (0.4023 g, 0.0022 mol) with 2,6-difluorobenzaldehyde (1.2 
equiv, 0.3837 g, 0.0027 mol) and piperidine (0.10 equiv, 26.7µL, 0.00027 mol) and 
EtOH (4 mL) with stirring.  The vial was placed on a 90 °C hot plate for 3 h. Product was 
recrystallized using acetic acid to afford a yellow solid (0.6062 g, 89%) collected via 
vacuum filtration; mp = 251-255 °C; Rf = 0.78 (EtOAc); 
1
H NMR (300 MHz, DMSO-d6) 
(s, 1H), 8.75 (s,1H), 8.21 (d, J = 8.7 Hz, 1H), 7.75-7.66 (m, 1H), 7.57 (s, 1H, 
Hvinyl), 7.36 (t, J = 8.34 Hz, 1H), 7.16 (t, J = 7.99 Hz, 1H), 7.07 (d, J = 8.69 Hz, 1H); 
13
C 
NMR : 167.77, 161.27-157.86 (dd, J = 7.24 Hz), 148.86, 141.87, 133.03 (t, J = 10.51 
Hz), 130.16, 127.20, 123.31, 120.89, 118.30, 112.48- 112.46 (dd, J = 6.41 Hz), 111.44- 
111.20 (t, J = 8.71 Hz), 110.27 ppm.     
 
(E)-3-(3,5-difluorobenzylidene)-5-nitroindolin-2-one (29)   
In a vial was combined 12 (0.1238 g, 0.00067 mol) with 3,5-difluorobenzaldehyde (1.2 
equiv, 0.1150 g, 0.00081 mol) and piperidine (0.10 equiv, 0.069 g, 0.000081 mol, 10.4 
L) and EtOH (1 mL) with stirring.  The vial was placed on a 90 °C hot plate for 3 hrs. 
Golden solid (0.1075 g, 53.1%) was collected via vacuum filtration: mp = 301-306 °C; Rf 
= 0.72 (EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  11.37 (s, 1H), 8.53 (s, 1H), 8.14-8.02 
(m, 1H), 7.71 (s, 1H, Hvinyl), 7.02 (d, J = 8.72 Hz, 1H, C-2‟), 6.96 (d, J = 8.53 Hz, 1H), 
2.51 (s, 1H).  
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(E)-3-(4-hydroxybenzylidene)-indolin-2-one (30)     
In a vial was combined 10 (0.2500 g, 0.0019 mol) with 4-hydroxybenzaldeyhde (1.2 
equiv, 0.2860 g, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH 
(2 mL) with stirring.  The vial was placed on a 90 °C hot plate for 3 h. A yellow solid 
(0.2706 g, 60%) was collected via vacuum filtration: mp = 298-301 °C (lit mp = 300+ 
°C)
28
; Rf = 0.43 (50:50 Hexanes:EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  10.91 (s, 
1H), 8.10 (d, J = 7.67 Hz, 1H),  8.03 (d, J = 8.47 Hz, 1H), 7.96 (s, 1H), 7.61 (d, J = 7.63 
Hz, 1H, C-2‟), 7.31 (d, J = 13.78 Hz, 1H), 7.31 (s, 1H, Hvinyl), 7.27 (d, J = 4.69 Hz, 1H); 
13
C NMR : 169.46, 159.67, 142.86, 132.17, 129.77, 125.41, 125.07, 122.41, 121.70, 
121.38, 116.31, 110.32 ppm. 
 
(Z)-3-((pyridin-4-yl)methylene)indolin-2-one (31)    
In a vial was combined 10 (0.2508 g, 0.0019 mol) with 4-pyridinecarboxaldehyde (1.2 
equiv, 217 µL, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH 
(2 mL) with stirring.  The vial was placed on a 90 °C hot plate for 3 h. A yellow solid 
(0.2524 g, 60%) was collected via vacuum filtration: mp = 226-229 °C (lit mp = 225-226 
°C)
29
; Rf = 0.12 (50:50 Hexanes:EtOAc); Compound 31 was a mixture of E and Z 
isomers, therefore an NMR spectrum could not be determined. 
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(E)-3-(4-methoxybenzylidene)indolin-2-one (32)    
In a vial was combined 10 (0.2532 g, 0.0019 mol) with p-anisaldehyde (1.2 equiv, 280 
µL, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH (2 mL) with 
stirring.  The vial was placed on a 90 °C hot plate for 3 h. A yellow solid (0.1463 g, 31%) 
was collected via vacuum filtration: mp = 152-155 °C (lit mp = 156-157 °C)
18,30
; Rf = 
0.17 (50:50 Hexanes:EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  10.56 (s, 1H), 7.67 (t, J 
= 8.92 Hz, 1H), 7.59 (s,1H, Hvinyl), 7.20 (t, J = 7.51 Hz, 1H), 7.06 (d, J= 8.07 Hz, 1H, C-
2‟), 6.87 (t, J = 5.99 Hz, 1H), 6.83 (s, 1H), 2.50 (s, 3H); 
13
C NMR : 168.93, 160.48, 
142.65, 135.94, 131.42, 129.59, 126.59, 125.61, 122.02, 121.16, 120.95, 114.17, 109.98, 
55.26 ppm.     
 
(E)-3-(2,6-difluorobenzylidene)indolin-2-one (33) (Procedure 1)   
In a vial was combined 10 (0.25 g, 0.0019 mol) with 2,6-difluorobenzaldehyde (1.1 
equiv, 0.2984 g, 0.0021 mol) and piperidine (10 equiv, 1.7882 g, 0.021 mol) and EtOH (2 
mL).  The vial was placed on a 70°C hot plate for 48 h.  Yellow solid (0.1032 g, 21.1%) 
was collected via vacuum filtration.  mp = 220-223°C; Rf = 0.65 (EtOAc); 
1
H NMR (300 
MHz, DMSO-d6) 10.73 (s, 1H), 7.67-7.57 (m, 1H), 7.34 (d, J = 14.5 Hz, 1H), 7.30 (d,  
J = 16.4, 1H), 7.24 (s, 1H, Hvinyl), 6.89 (dd, J = 15.3 and 7.5 Hz, 1H); 
13
C NMR : 
167.53, 161.32-157.92 (dd, J = 7.02 Hz), 143.23, 132.29, 131.93 (t, J = 10.44 Hz), 
130.80, 123.09, 121.46, 120.70, 119.71, 112.25- 111.75 (d, J = 24.64 Hz), 112.16- 
111.75 (t, J = 19.74 Hz), 110.12 ppm.   
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(E)-3-(2,6-difluorobenzylidene)indolin-2-one (33) (Procedure 2)    
In a vial was combined 10 (0.25 g, 0.0019 mol) with 2,6-difluorobenzaldehyde (1.2 
equiv, 0.3240 g, 0.00228 mol) and piperidine (0.10 equiv, 0.0194 g, 0.000228 mol) and 
EtOH (2 mL) with stirring.  The vial was placed on a 90 °C hot plate for 3 h. Yellow 
solid (0.3929 g, 79%) was collected via vacuum filtration. mp = 210-215 °C; Rf = 0.69 
(EtOAc); 
1
H NMR (300 MHz, CDCl3-d1)  8.27 (s, 1H), 7.47-7.37 (m, 1H), 7.26 (s, 1H, 
Hvinyl), 7.23 (d, J = 8.16 Hz, 1H), 7.05 (dd, J = 15.3 and 7.5 Hz, 1H), 6.89 (d, J = 7.84 
Hz, 1H); 
13
C NMR : 167.53, 161.32-157.92 (dd, J = 7.02 Hz), 143.23, 132.29, 131.93 (t, 
J = 10.44 Hz), 130.80, 123.09, 121.46, 120.70, 119.71, 112.25- 111.75 (d, J = 24.64 Hz), 
112.16- 111.75 (t, J = 19.74 Hz), 110.12 ppm.   
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(E)-3-(2,6-difluorobenzylidene)indolin-2-one (33) (Microwave Synthesis)  
To a Glasschem 20 vessel with a stir bar was added 10 (0.5 g, 0.0038 mol) with 2,6-
difluorobenzaldehyde (1.2 equiv, 0.6480 g, 0.00456 mol) and piperidine (0.10 equiv, 
0.0388 g, 0.000456 mol) and EtOH (4 mL).  The power on the MARS Glasschem 
Microwave was set to 300W, ramp to temp time = 2:00 min., hold temp = 5:00 min., set 
temp = 140°C and stir bar speed = 3 (high).  These parameters were collectively saved as 
method name “Hagar”. Yellow solid (0.5369 g, 55.3%) was collected via vacuum 
filtration.  mp =  213-218 °C; Rf = 0.85 (EtOAc);
 1
H NMR (300 MHz, DMSO-d6)  10.72 
(s, 1H), 7.68-7.58 (m, 1H), 7.34 (d, J = 3.7 Hz, 1H), 7.31 (s, 1H, Hvinyl), 7.25 (d, J = 2.08 
Hz, 1H), 6.89 (dd, J = 14.4 and 7.1 Hz, 1H); 
13
C NMR : 167.53, 161.32-157.92 (dd, J = 
7.02 Hz), 143.23, 132.29, 131.93 (t, J = 10.44 Hz), 130.80, 123.09, 121.46, 120.70, 
119.71, 112.25- 111.75 (d, J = 24.64 Hz), 112.16- 111.75 (t, J = 19.74 Hz), 110.12 ppm.  
Anal. Calcd for C15H9NOF2:  C, 70.04; H, 3.53; N, 5.45. Found:  C, 69.90; H, 3.71; N, 
5.62 
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(E)-3-(3,5-difluorobenzylidene)indolin-2-one (34)   
In a vial was combined 10 (0.2998 g, 0.0023 mol) with 3,5-difluorobenzaldehyde (1.2 
equiv, 0.4170 g, 0.0027 mol) and piperidine (0.10 equiv, 0.023 g, 0.00027 mol, 27 L) 
and EtOH (2 mL) with stirring.  The vial was placed on a 90 °C hot plate for 3 hrs. 
Golden solid (0.2819 g, 47.6%) was collected via vacuum filtration: mp = 202-205 °C; Rf 
= 0.79 (EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  10.68 (s, 1H), 8.10 (d, J = 7.56 Hz, 
1H), 7.72 (s, 1H, Hvinyl), 7.65 (d, J = 7.56 Hz, 1H, C-2‟), 8.14-8.01 (m, 1H), 6.98 (dd, J = 
20.12 Hz, 9.15 Hz, 1H); Anal. Calcd for C15H9NOF2:  C, 70.04; H, 3.53; N, 5.45. Found:  
C, 69.65; H, 3.69; N, 5.42.    
 
(E)-3-(2,3-dichlorobenzylidene)indolin-2-one (35)     
In a vial was combined 10 (0.2497 g, 0.0019 mol) with 2,3-dichlorobenzaldehyde (1.2 
equiv, 0.3945 g, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH 
(2 mL) with stirring.  The vial was placed on a 90 °C hot plate for 3 h. A yellow-orange 
solid (0.4807 g, 89%) was collected via vacuum filtration: mp = 263-265 °C; Rf = 0.68 
(50:50 Hexanes:EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  10.70 (s, 1H), 7.75 (d, J = 
8.00 Hz, 1H), 7.72 (d, J = 7.64 Hz, 1H), 7.55 (s, 1H, Hvinyl), 7.51 (t, J = 7.93 Hz, 1H), 
7.24 (t, J = 7.67 Hz, 1H), 7.07 (d, J = 7.64 Hz, 1H, C-6‟), 6.88 (d, J = 7.78 Hz, 1H), 6.81 
(t, J = 7.64 Hz, 1H)      
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 (E)-3-benzylideneindolin-2-one (36)     
In a vial was combined 10 (0.2515 g, 0.0019 mol) with benzaldehyde (1.2 equiv, 0.4283 
g, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH (2 mL) with 
stirring.  The vial was placed on a 90 °C hot plate for 3 h. A yellow solid (0.3831 g, 62%) 
was collected via vacuum filtration: mp = 172-175 °C (lit mp = 175-176 °C)
30,31
; Rf = 
0.41 (50:50 Hexanes:EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  10.61 (s, 1H), 7.69 (d, J 
= 7.26 Hz, 1H), 7.64 (s, 1H, Hvinyl), 7.49 (t, J = 7.62 Hz, 1H), 7.22 (t, J = 7.67 Hz, 1H), 
6.88 (d, J = 7.98 Hz, 1H, C-2‟), 6.83 (t, J = 7.65 Hz, 1H).   
 
(Z)-3-(4-nitrobenzylidene)indolin-2-one (37)      
In a vial was combined 10 (0.2503 g, 0.0019 mol) with 4-nitrobenzaldehyde (1.2 equiv, 
214 µL, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH (2 mL) 
with stirring.  The vial was placed on a 90 °C hot plate for 3 h. A yellow solid (0.2785 g, 
68%) was collected via vacuum filtration: mp = 251-252 °C (lit mp = 252-253 °C)
30
; Rf = 
0.41 (50:50 Hexanes:EtOAc); 
1
H NMR (300 MHz, DMSO-d6) 10.68 (s, 1H), 8.32 (d, J 
= 8.24 Hz, 1H, C-2‟), 7.93 (d, J = 8.19 Hz, 1H), 7.65 (s, 1H, Hvinyl), 7.39 (d, J = 8.24 Hz, 
1H), 7.49 (d, J = 7.48 Hz, 1H), 7.25 (t, J = 7.42 Hz, 1H), 6.86 (t, J = 8.31 Hz, 1H)  
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(Z)-3-(2-fluoro-5-nitrobenzylidene)indolin-2-one (38)      
In a vial was combined 10 (0.2507 g, 0.0019 mol) with 2-fluoro-5-nitrobenzaldehyde (1.2 
equiv, 0.3834 g, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH 
(2 mL) with stirring.  The vial was placed on a 90 °C hot plate for 3 h. A yellow solid 
(0.3472 g, 65%) was collected via vacuum filtration: mp = 199-201 °C; Rf = 0.59 (50:50 
Hexanes:EtOAc); 
1
H NMR (300 MHz, DMSO-d6) 10.60 (s, 1H), 8.33 (s, 1H, C-6‟), 
8.02 (d, J = 7.65 Hz, 1H), 7.64 (d, J = 8.42 Hz, 1H), 7.40 (d, J = 8.24 Hz, 1H), 7.33 (s, 
1H, Hvinyl), 7.25 (d, J = 7.61 Hz, 1H), 6.84 (t, J = 7.84 Hz, 1H).   
 
(E)-3-(2-chloro-3,6-difluorobenzylidene)indolin-2-one (39)     
In a vial was combined 10 (0.2497 g, 0.0019 mol) with 2-chloro-3,6-
difluorobenzaldehyde (1.2 equiv, 0.3993 g, 0.0023 mol) and piperidine (0.10 equiv, 
0.00023 mol, 23 L) and EtOH (2 mL) with stirring.  The vial was placed on a 90 °C hot 
plate for 3 h. A yellow solid (0.3472 g, 65%) was collected via vacuum filtration: mp = 
199-201 °C; Rf = 0.59 (50:50 Hexanes:EtOAc); 
1
H NMR (300 MHz, DMSO-d6)  10.53 
(s, 1H), 7.79 (d, J = 8.24 Hz, 1H), 7.54 (s, 1H, Hvinyl), 7.46 (d, J = 7.61 Hz, 1H), 7.22 (t, J 
= 8.01 Hz, 1H), 7.17 (t, J = 7.57 Hz, 1H), 7.08 (d, J = 7.76 Hz, 1H), 6.95 (d, J = 7.24 Hz, 
1H) 
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(E)-3-(2,3,5-trichlorobenzylidene)indolin-2-one (40)     
In a vial was combined 10 (0.2515 g, 0.0019 mol) with 2,3,5-trichlorobenzaldehyde (1.2 
equiv, 0.4283 g, 0.0023 mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH 
(2 mL) with stirring.  The vial was placed on a 90 °C hot plate for 3 h. An orange solid 
(0.3831 g, 62%) was collected via vacuum filtration: mp = 268-270 °C; Rf = 0.60 (50:50 
Hexanes:EtOAc); Compound 40 would not dissolve in any of the deuterated NMR 
solvents, therefore an NMR spectrum could not be generated. 
 
2,6-difluoro-3-nitrobenzaldehyde (42)  
Sulfuric acid (11mL) was added to a beaker and cooled in an ice bath so that the 
temperature did not exceed 5 °C.  2,6-Difluorobenzaldehyde (2.4 mL, 0.0222 mol) was 
added to the beaker dropwise.  Nitric acid (900 µL) was added to the beaker and the 
solution was left to stir for 1 h.  The product (off-white) was collected by vacuum 
filtration (0.7104 g, 17%); mp = 59-61 °C; Rf = 0.62 (50:50 Hexanes:EtOAc);
 1
H NMR 
(300 MHz, DMSO-d6) 10.20 (s, 1H), 8.56-8.48 (m, 1H), 7.51 (t, J = 9.51 Hz, 1H).   
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(E)-3-(2,6-difluoro-3-nitrobenzylidene)indolin-2-one (43)   
In a vial was combined 10 (0.2571 g, 0.0019 mol) with 42 (1.2 equiv, 0.4324 g, 0.0023 
mol) and piperidine (0.10 equiv, 0.00023 mol, 23 L) and EtOH (2 mL) with stirring.  
The vial was placed on a 90 °C hot plate for 3 h. A yellow solid (0.0705 g, 12%) was 
collected via vacuum filtration: mp = 220-225 °C; Rf = 0.46 (50:50 Hexanes:EtOAc); 
1
H 
NMR (300 MHz, DMSO-d6) 10.45 (s, 1H), 8.00 (d, J = 9.40 Hz, 1H), 7.70 (d, J = 7.49 
Hz, 1H), 7.47 (s, 1H, Hvinyl), 7.23 (t, J = 7.66 Hz1H), 6.99 (t, J = 7.53 Hz, 1H), 6.83 (d, 
J = 7.74 Hz, 1H), 6.59 (d, J = 9.41 Hz, 1H). 
   
7-Nitroindolin-2-one (45)    
In a vial was combined 8-nitroquinoline (1.9998 g, 0.0115 mol) with acetic acid (16 mL) 
and 30% H2O2 (4 mL) and placed on a hot plate at 70 °C for 4 h.  30% H2O2 (4 mL) was 
added and left on the hot plate at 70 °C for another 4 h. A brown solid (0.2898 g, 14%) 
was collected via vacuum filtration: mp = 249-253 °C (lit mp = 256-257 °C)
41
; Rf = 0.16 
(50:50 Hexanes:EtOAc); 
1
H and 
13
C NMR were not determined in time for this report.  
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